AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25951368 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop-Only-While-Shocking (SOWS) algorithm
Number of subjects: 29
Study 25951368 — intervention group
Group type: COMPARATOR
Intervention: European Resuscitation Council (ERC) 2010 algorithm
Number of subjects: 29
Study 25911824 — intervention group
Group type: EXPERIMENTAL
Intervention: Child anorexia granule (1 package bid for 1-3 years, 1 package tid for 4-6 years, po, 4 weeks)
Number of subjects: 81
Study 25911824 — intervention group
Group type: COMPARATOR
Intervention: Domperidone suspension (0.3 mg x kg(-1) x d(-1), tid, orally 30 minutes before meals)
Number of subjects: 81
Study 22001231 — intervention group
Group type: COMPARATOR
Intervention: Behavioral interventions
Number of subjects: 46
Study 20687954 — intervention group
Group type: EXPERIMENTAL
Intervention: Duet cervical barrier used continuously for 14 days
Number of subjects: 103
Study 20687954 — intervention group
Group type: EXPERIMENTAL
Intervention: Duet cervical barrier used precoitally for 14 days
Number of subjects: 103
Study 20687954 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 103
Study 17917611 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg oral capsules three times daily for 4 weeks
Number of subjects: 200
Study 17917611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 17917611 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg oral capsules
Number of subjects: 200
Study 16827248 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane with nitrous oxide
Number of subjects: 48
Study 16827248 — intervention group
Group type: COMPARATOR
Intervention: Enflurane without nitrous oxide
Number of subjects: 48
Study 16827248 — intervention group
Group type: COMPARATOR
Intervention: Age influence
Number of subjects: 48
Study 16827248 — intervention group
Group type: COMPARATOR
Intervention: Weight influence
Number of subjects: 48
Study 16827248 — intervention group
Group type: COMPARATOR
Intervention: ASA status influence
Number of subjects: 48
Study 16827248 — intervention group
Group type: COMPARATOR
Intervention: Gender influence
Number of subjects: 48
Study 12839718 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Danger Ideation Reduction Therapy (DIRT)
Number of subjects: 0
Study 11106211 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak flow manoeuvre (PEFPF)
Number of subjects: 80
Study 11106211 — intervention group
Group type: COMPARATOR
Intervention: Forced vital capacity manoeuvre (PEFVC)
Number of subjects: 80
Study 9002088 — intervention group
Group type: EXPERIMENTAL
Intervention: Steep lens fitting protocol
Number of subjects: 30
Study 1642348 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful stimulation via tetanic electrical stimulation
Number of subjects: 0
Study 1642348 — intervention group
Group type: COMPARATOR
Intervention: No painful stimulation (control)
Number of subjects: 0
Study 3516447 — intervention group
Group type: EXPERIMENTAL
Intervention: Björk-Shiley valve
Number of subjects: 540
Study 3516447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hancock valve
Number of subjects: 540
Study 3516447 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpentier-Edwards valve
Number of subjects: 540
Study 3516447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Number of subjects: 540
Study 3516447 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement
Number of subjects: 540
Study 3516447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral plus aortic valve replacement
Number of subjects: 540
Study 3516447 — intervention group
Group type: COMPARATOR
Intervention: All prostheses
Number of subjects: 540
Study 3516447 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients with Björk-Shiley prostheses
Number of subjects: 540
Study 3516447 — intervention group
Group type: COMPARATOR
Intervention: Reoperation for valve failure
Number of subjects: 540
Study 29959110 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative-only analysis for drug question (n=58)
Number of subjects: 126
Study 29959110 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP analysis for drug question
Number of subjects: 126
Study 29959110 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and NLP-augmented analysis for drug question
Number of subjects: 126
Study 29959110 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative-only analysis for police question (n=68)
Number of subjects: 126
Study 29959110 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP-only analysis for police question
Number of subjects: 126
Study 29959110 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and NLP-augmented analysis for police question
Number of subjects: 126
Study 29959110 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP-only approach for drug question
Number of subjects: 126
Study 29959110 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative-only approach for drug question
Number of subjects: 126
Study 29959110 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP-only approach for police question
Number of subjects: 126
Study 29959110 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative-only approach for police question
Number of subjects: 126
Study 29959110 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis followed by qualitative- or NLP-augmented analysis for drug question
Number of subjects: 126
Study 29959110 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP analysis followed by qualitative analysis for drug question
Number of subjects: 126
Study 29959110 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis followed by qualitative- or NLP-augmented analysis for police question
Number of subjects: 126
Study 29959110 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP analysis followed by qualitative analysis for police question
Number of subjects: 126
Study 26849462 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look endoscopy (SLE)
Number of subjects: 220
Study 26849462 — intervention group
Group type: COMPARATOR
Intervention: Non-second-look endoscopy (non-SLE)
Number of subjects: 220
Study 26849462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SLE and non-SLE)
Number of subjects: 220
Study 24141698 — intervention group
Group type: EXPERIMENTAL
Intervention: palonosetron 0.25 or 0.75 mg
Number of subjects: 2962
Study 24141698 — intervention group
Group type: COMPARATOR
Intervention: palonosetron 0.25 mg
Number of subjects: 2962
Study 24141698 — intervention group
Group type: COMPARATOR
Intervention: palonosetron 0.75 mg
Number of subjects: 2962
Study 22711895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ROX-828 (31.5 mg ketorolac tromethamine/200 µL, containing 6% of lidocaine)
Number of subjects: 140
Study 22711895 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with 6% lidocaine)
Number of subjects: 140
Study 22711895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ROX-828
Number of subjects: 140
Study 21799442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg/day
Number of subjects: 26
Study 21799442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 19226292 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO(4).IV
Number of subjects: 40
Study 19226292 — intervention group
Group type: COMPARATOR
Intervention: MgSO(4)/L
Number of subjects: 40
Study 16838873 — intervention group
Group type: EXPERIMENTAL
Intervention: Curvex toothbrush
Number of subjects: 21
Study 16838873 — intervention group
Group type: COMPARATOR
Intervention: Oral-B Indicator 40 toothbrush
Number of subjects: 21
Study 12908666 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment added to existing treatment options
Number of subjects: 0
Study 12908666 — intervention group
Group type: COMPARATOR
Intervention: Existing treatment options
Number of subjects: 0
Study 10821991 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of oral carvedilol
Number of subjects: 12
Study 10821991 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg carvedilol
Number of subjects: 12
Study 10821991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10821991 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg carvedilol
Number of subjects: 12
Study 9554136 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser correction using erodible masks
Number of subjects: 83
Study 1347582 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirst-guided drinking
Number of subjects: 8
Study 1347582 — intervention group
Group type: COMPARATOR
Intervention: Forced drinking (chilled water every 15-20 min)
Number of subjects: 8
Study 3899771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release clomipramine (Anafranil SR) 75 mg once daily
Number of subjects: 46
Study 3899771 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation of clomipramine (Anafranil) 75 mg once daily
Number of subjects: 46
Study 31357225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chairside digital workflow with monolithic lithium disilicate (LS2) crowns
Number of subjects: 33
Study 31357225 — intervention group
Group type: COMPARATOR
Intervention: Hybrid digital workflow with CAD/CAM-fabricated zirconia superstructures and hand-layered ceramic veneering crowns
Number of subjects: 33
Study 30166228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Docetaxel (Arm A)
Number of subjects: 12
Study 30166228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Gemcitabine (Arm B)
Number of subjects: 12
Study 30166228 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 12
Study 27329547 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional barbed suture (V‐Loc 180; Covidien, Mansfield, MA)
Number of subjects: 40
Study 27329547 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture (Vicryl; Ethicon, Somerville, NJ)
Number of subjects: 40
Study 24820768 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide (MgO) alone
Number of subjects: 71
Study 24820768 — intervention group
Group type: COMPARATOR
Intervention: Magnesium oxide (MgO) with H2 receptor antagonist (H2RA)
Number of subjects: 71
Study 24820768 — intervention group
Group type: COMPARATOR
Intervention: Magnesium oxide (MgO) with proton pump inhibitor (PPI)
Number of subjects: 71
Study 23106931 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 175
Study 23106931 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 175
Study 23106931 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-positive subjects
Number of subjects: 175
Study 23106931 — intervention group
Group type: COMPARATOR
Intervention: HCV-negative subjects
Number of subjects: 175
Study 20930341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone irrigation
Number of subjects: 16
Study 20930341 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine irrigation
Number of subjects: 16
Study 18931244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary block with negative aspiration for blood
Number of subjects: 0
Study 18931244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary block with visualization of local anesthetic spread
Number of subjects: 0
Study 15975759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy (IPEC) consisting of doxorubicin, 0.1mg/kg and cisplatin, 15 mg/m² per day for 5 consecutive days.
Number of subjects: 38
Study 15975759 — intervention group
Group type: COMPARATOR
Intervention: Control group (cytoreduction alone).
Number of subjects: 38
Study 12416649 — intervention group
Group type: EXPERIMENTAL
Intervention: Zygote transfer
Number of subjects: 386
Study 12416649 — intervention group
Group type: COMPARATOR
Intervention: Embryo transfer
Number of subjects: 386
Study 10469101 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of pulsed CO2 laser followed by Q-switched alexandrite laser
Number of subjects: 8
Study 10469101 — intervention group
Group type: COMPARATOR
Intervention: Pulsed CO2 laser only
Number of subjects: 8
Study 7563337 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 sterile powder
Number of subjects: 0
Study 7563337 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 sterile solution
Number of subjects: 0
Study 7563337 — intervention group
Group type: COMPARATOR
Intervention: Pediatric sterile solution (placebo)
Number of subjects: 0
Study 7563337 — intervention group
Group type: COMPARATOR
Intervention: 0 microgram (placebo)
Number of subjects: 0
Study 7563337 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 micrograms
Number of subjects: 0
Study 7563337 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms
Number of subjects: 0
Study 7563337 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms
Number of subjects: 0
Study 7563337 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms
Number of subjects: 0
Study 2248533 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 29
Study 2248533 — intervention group
Group type: COMPARATOR
Intervention: Control (no prednisolone)
Number of subjects: 29
Study 6264865 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms ethinyl estradiol
Number of subjects: 14
Study 6264865 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinyl estradiol
Number of subjects: 14
Study 6264865 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms ethinyl estradiol
Number of subjects: 14
Study 6264865 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 micrograms ethinyl estradiol
Number of subjects: 14
Study 6264865 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 micrograms estriol
Number of subjects: 14
Study 6264865 — intervention group
Group type: EXPERIMENTAL
Intervention: 1250 micrograms conjugated estrogens
Number of subjects: 14
Study 31679946 — intervention group
Group type: EXPERIMENTAL
Intervention: Elexacaftor 200 mg orally once daily plus tezacaftor 100 mg orally once daily plus ivacaftor 150 mg orally every 12 h
Number of subjects: 107
Study 31679946 — intervention group
Group type: EXPERIMENTAL
Intervention: Elexacaftor plus tezacaftor plus ivacaftor
Number of subjects: 107
Study 31679946 — intervention group
Group type: COMPARATOR
Intervention: Tezacaftor plus ivacaftor
Number of subjects: 107
Study 27485100 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + fluoxetine
Number of subjects: 62
Study 27485100 — intervention group
Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 62
Study 27485100 — intervention group
Group type: COMPARATOR
Intervention: CBT + placebo
Number of subjects: 62
Study 26384639 — intervention group
Group type: EXPERIMENTAL
Intervention: PEM 0.5%, 1%, 2%
Number of subjects: 0
Study 26384639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23375165 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine A (types 1:2:3 = 3:100:100 DU)
Number of subjects: 0
Study 23375165 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine B (types 1:2:3 = 1.5:50:50 DU)
Number of subjects: 0
Study 23375165 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine C (types 1:2:3 = 0.75:25:25 DU)
Number of subjects: 0
Study 23375165 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-sIPV (with sIPV antigens)
Number of subjects: 0
Study 21441782 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV (3 doses)
Number of subjects: 240
Study 21441782 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV (booster)
Number of subjects: 240
Study 21441782 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV (2-dose catch-up)
Number of subjects: 240
Study 21441782 — intervention group
Group type: COMPARATOR
Intervention: HAV (control)
Number of subjects: 240
Study 19944004 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with no-updosing regimen
Number of subjects: 0
Study 19944004 — intervention group
Group type: COMPARATOR
Intervention: Sublingual immunotherapy (SLIT) with traditional updosing approach
Number of subjects: 0
Study 16816491 — intervention group
Group type: EXPERIMENTAL
Intervention: C. pen and gentamicin intravenously (IV), followed by oral amoxicillin
Number of subjects: 71
Study 16816491 — intervention group
Group type: COMPARATOR
Intervention: amox-clav IV, followed by oral amox-clav
Number of subjects: 71
Study 14594793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal amino acid solution (2 L, 1.1%)
Number of subjects: 13
Study 14594793 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal glucose solution (2.27%)
Number of subjects: 13
Study 10669270 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with ketobemidone
Number of subjects: 48
Study 10669270 — intervention group
Group type: COMPARATOR
Intervention: Nurse-controlled analgesia (NCA) with ketobemidone
Number of subjects: 48
Study 9380790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (900 mg/day)
Number of subjects: 0
Study 9380790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8362600 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. rIL-2 at doses of 4.8-14.4 million IU/m2/day on 5 days per week
Number of subjects: 107
Study 8362600 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. rIL-2 in combination with s.c. rIFN-alpha at 14.4-18.0 million IU/m2/day on days 1 and 2, followed by 4.8 million IU/m2/day, 5 days per week
Number of subjects: 107
Study 2433307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gammaglobulin (IVGG) plus aspirin (ASA)
Number of subjects: 0
Study 2433307 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA) alone
Number of subjects: 0
Study 28985310 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation implementation intervention for staff
Number of subjects: 12490
Study 26595503 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic naso-gallbladder drainage (ENGBD)
Number of subjects: 35
Study 26595503 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic gallbladder stenting (EGBS)
Number of subjects: 35
Study 24562873 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based followup
Number of subjects: 229
Study 24562873 — intervention group
Group type: COMPARATOR
Intervention: Usual-care (in-person followup)
Number of subjects: 229
Study 24562873 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for followup method
Number of subjects: 229
Study 24312458 — intervention group
Group type: EXPERIMENTAL
Intervention: Early IUGR
Number of subjects: 102
Study 24312458 — intervention group
Group type: EXPERIMENTAL
Intervention: Late IUGR (VD)
Number of subjects: 102
Study 24312458 — intervention group
Group type: EXPERIMENTAL
Intervention: Late IUGR (non-VD)
Number of subjects: 102
Study 24312458 — intervention group
Group type: EXPERIMENTAL
Intervention: All IUGR subforms
Number of subjects: 102
Study 24312458 — intervention group
Group type: COMPARATOR
Intervention: AGA
Number of subjects: 102
Study 20395260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) Q5 (>5.1-6.9 mmol/L)
Number of subjects: 6447
Study 20395260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) Q5e (5.8-6.9 mmol/L)
Number of subjects: 6447
Study 18962988 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day for 6 weeks
Number of subjects: 30
Study 18962988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15478314 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E2 valerate 2-4 mg/day
Number of subjects: 20
Study 15478314 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2 50-100 microg/day
Number of subjects: 20
Study 11487675 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (2 mg per 2 mL)
Number of subjects: 149
Study 11487675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 9777425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular cyanocobalamin injections
Number of subjects: 50
Study 9777425 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 50
Study 7828216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral chest wall temperature
Number of subjects: 0
Study 7828216 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary temperature
Number of subjects: 0
Study 7828216 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal temperature
Number of subjects: 0
Study 7828216 — intervention group
Group type: COMPARATOR
Intervention: Sitting (activity)
Number of subjects: 0
Study 7828216 — intervention group
Group type: COMPARATOR
Intervention: Standing or walking (activity)
Number of subjects: 0
Study 7828216 — intervention group
Group type: COMPARATOR
Intervention: Exercising (activity)
Number of subjects: 0
Study 3046651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative prophylactic dose of a combination of crystalline penicillin and chloramphenicol
Number of subjects: 232
Study 3046651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 30341773 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CPP-ACP crème applied three times daily
Number of subjects: 24
Study 30341773 — intervention group
Group type: COMPARATOR
Intervention: Placebo crème without CPP-ACP
Number of subjects: 24
Study 27849566 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 400 mg once daily for 4 weeks
Number of subjects: 72
Study 27849566 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 320 mg once daily for 4 weeks
Number of subjects: 72
Study 26306691 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered systematic drug review intervention by trained primary care physicians (PCPs)
Number of subjects: 0
Study 26306691 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a lecture on multimorbidity and instructions for usual care
Number of subjects: 0
Study 23777957 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-resistance training exercise of knee extension (five sets of eight repetitions with 80% of one-repetition maximum, three sessions a week for 12 weeks)
Number of subjects: 0
Study 23777957 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 21227601 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 0
Study 21227601 — intervention group
Group type: EXPERIMENTAL
Intervention: Client motivation at the beginning of the session
Number of subjects: 0